{'fraction_non_alphanumeric': 0.0346611484738748, 'fraction_numerical': 0.021210553543714435, 'mean_word_length': 5.120253164556962, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prospective Evaluation of Focal High-Intensity Focused Ultrasound (HIFU) for Patients with Localized Prostate Cancer.

PURPOSE
We report short-term outcomes of focal high-intensity focused ultrasound use for primary treatment of localized prostate cancer.


MATERIALS AND METHODS
Single-center prospectively collected prostate cancer patients who underwent primary focal HIFU from January 2016 to July 2018 were included. All patients underwent a 12-core biopsy with MRI-US fusion biopsy depending on the presence of targetable lesions. Any Grade Group was allowed; however, only patients with localized disease were included. The primary outcome was oncologic control, defined as negative follow-up infield biopsy of treated cancer. PSA, SHIM, IPSS and EPIC domain scores were assessed 3-monthly till 12 months. Biopsy was performed at 6 or 12 months for high- or low/intermediate-risk cancer, respectively.


RESULTS
Fifty-two patients with minimum follow-up of 12 months were included in the study. Majority (67%) of patients had cancer Grade Group 2 or greater. Fifteen patients (28.8%) underwent complete TURP/HoLEP procedure for debulking large prostates to avoid postoperative urinary retention. Among 30 (58%) patients who underwent follow-up biopsies, 25 (83%) had negative infield biopsy results. 4 (13%) had de-novo positive outfield biopsy. Only 5 major complications (all Grade III) in 4 patients were noted. Urinary symptoms returned to near baseline questionnaire scores within 3-6 months. Sexual function returned to baseline at 12 months.


CONCLUSIONS
Focal HIFU is a safe and effective treatment for patients with localized clinically significant prostate cancer with acceptable short-term oncological and functional outcomes. The complications are minimal and patient selection is essential. Short-term oncological outcomes are promising but longer follow-up is required to establish long-term oncologic outcomes.